Request Trial
sunpharma
Photo: Courtesy of Sun Pharmaceutical (http://www.sunpharma.com/media/media-kit)
2 February 2016Americas

Generic Gleevec launches in US

India-based Sun Pharmaceutical has launched its generic version of Novartis’s cancer treatment drug Gleevec (imatinib) in the US.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
9 March 2026   Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026   The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.
Americas
Moderna inks billion-dollar deal to settle long-running Spikevax dispute
5 March 2026   Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

Arnold & Porter adds tech litigator in San Francisco
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
Nomination call: Influential Women in IP list closes ahead of International Women’s Day
Abbott IP chief: ‘Firms without AI policies scare me’
Moderna inks billion-dollar deal to settle long-running Spikevax dispute
DWT recruits first-chair trial litigator as latest hire in IP expansion